Deferasirox therapy is associated with reduced mortality risk in a medicare population with myelodysplastic syndromes
Amer M. Zeidan(Yale Cancer Center), Amy J. Davidoff, Maria R. Baer(University of Maryland, Baltimore), Medha Sasané(Novartis (United States)), Carole Paley(Roswell Park Comprehensive Cancer Center), Franklin Hendrick(University of Maryland, Baltimore), Erika Friedmann(University of Maryland, College Park), Steven D. Gore(Yale Cancer Center)
Cited by 45
Related Papers
Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i> -Mutated AML
|New England Journal of Medicine|2019|1.3k
Azacitidine Prolongs Overall Survival Compared With Conventional Care Regimens in Elderly Patients With Low Bone Marrow Blast Count Acute Myeloid Leukemia
|Journal of Clinical Oncology|2009|963
KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study
|The Lancet|2021|795
<i>IDH1</i> and <i>IDH2</i> Gene Mutations Identify Novel Molecular Subsets Within De Novo Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study
|Journal of Clinical Oncology|2010|764
Acute Myeloid Leukemia, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2017|655